Abstract Dubin-Johnson syndrome is a recessive inherited disorder with conjugated hyperbilirubinemia caused by a dysfunction of multidrug resistance protein 2 (MRP2) on the canalicular membrane of hepatocytes. A mutational analysis of the MRP2 gene was carried out in three Japanese patients and their family members. In two patients, the homozygous mutations c.1901del67 and c,2272del168 were found. In the third patient, a )24C fi T polymorphism and the two mutations c.1901del67 and 2026G fi C were detected. The 2026G fi C mutation was a novel mutation in exon 16 affecting the conversion of Gly 676 to Arg 676 (G676R) in the MRP2 protein, and was not detected in fifty healthy volunteers. The G676R mutation was located in the Walker A motif of the first nucleotide binding domain in the MRP2 protein, and it was suggested that the mutation induced the dysfunction of the MRP2 protein. It was concluded that the compound heterozygosity of the two mutations of the MRP2 gene in the third patient contributed to the induction of hyperbilirubinemia in this case.
Introduction
Dubin-Johnson syndrome (DJS) is an inherited metabolic disorder characterized by conjugated hyperbilirubinemia and a re-increase of serum bromosulfophtalein (BSP) in the BSP tolerance test, characteristics that are caused by a dysfunction of the canalicular multispecific anion transporter (cMOAT, multidrug resistance protein 2; MRP2).
The human MRP2 gene was identified in cisplatinresistant tumor cells by Taniguchi et al. (1996) following the identification of the rat cmoat (mrp2) gene in hyperbilirubinemia rats (TR ) rats) by Paulusma et al. (1996) . The human MRP2 gene was mapped to chromosome 10 at q24 (Taniguchi et al. 1996) and was found to consist of 32 exons (Toh et al. 1999) .
MRP2 protein is a membrane protein with 1545 amino acids; it contains two ATP-binding cassettes (ABCs) and 17 transmembrane sequences (Taniguchi et al. 1996) . It is expressed at the canalicular membrane of hepatocytes and apical membrane of the renal uriniferous tuble (Paulusma et al.1996) and is involved in the excretion of glucronide-conjugated bilirubin and glutathione-conjugates from the liver (Taniguchi et al. 1996; Wada et al. 1998) .
The first mutation of the MRP2 gene causing hyperbilirubinemia was found by Paulusma et al. (1997) in DJS, and a total of 10 mutations have been found as listed in Table 1 .
In the present study, we conducted a mutational analysis in three Japanese DJS patients and found two known deletion mutations (c.1901del67, c.2272del168 ) and a novel missense mutation of G676R in the first nucleotide-binding domain (NBD1) in the MRP2 protein.
Patient 1 (DJ1) was a male whose parents were distantly related. He was diagnosed with DJS at the age of 28 years based on hyperbilirunemia, a BSP test, and a histological examination of the liver. Serum bilirubin values of his two daughters and spouse were within the normal range.
Patient 2 (DJ2) was a female whose parents were the first cousins. She was diagnosed with DJS at the age of 23 years based on hyperbilirunemia, a BSP test, and a histological examination of the liver. Serum bilirubin values of her two siblings, daughter, and spouse were within the normal range.
Patient 3 (DJ3) was a male whose parents were distantly related. He was diagnosed with chronic hepatitis and DJS at the age of 25 years based on serum aminotransferase levels, conjugated hyperbilirunemia, a BSP test, and a histological examination of the liver. Thereafter, he was diagnosed as having DJS with chronic hepatitis C from positive results for anti-HCV antibody and HCV RNA. Among his two daughters, spouse, and six siblings, there was only a moderate hyperbilirubinemia in his older sister.
Mutational analyses mRNA analysis
Total RNA was extracted from peripheral white blood cells with an Isogen WB kit (Wako Pure Chemicals, Japan), and cDNA was obtained by reverse transcription of 1 lg RNA with M-MLV transcriptase, RNase inhibitor (RNaseOUT, Invitrogen, Carlsbad, Calif.), and random hexamer primers (Invitrogen). Polymerase chain reaction (PCR) was performed with Taq DNA polymerase (Promega, Tokyo, Japan) and twelve primer sets originally reported by Wada et al. (1998) . PCR products were separated on a 1.5% agarose gel by electrophoresis and directly sequenced by a Sequencing High detection kit (Toyobo, Tokyo, Japan).
Genomic DNA analysis
Genomic DNA was isolated from peripheral white blood cells with a DNA isolation kit (Puregene Blood Kit, Gentra Systems, Minneapolis, Minn.) and used for PCR amplification of 32 exons with flanking intronic regions by the primer sets reported by Toh et al. (1999) . Direct sequencing analysis was performed by ABI PRISM Dye Terminators in an ABI 3700 Genetic Analyzer (Applied Biosystems, Foster City, Calif.).
Segregation of a novel mutation within the family A mismatch primer set was used for the novel mutation site. The primers used to detect the mutation were the forward primer 5'-gataggccctgtcggctctC-3' (the underlined sequence indicates the mismatched site) and the reverse primer 5'-gggaaggagaatcacagtccaca-3'. PCRs were conducted with 30 cycles of 30 s denaturation at 95°C, 30 s anneraling at 66°C, and 30 s extension at 74°C. PCR products of 234 bp were detected by electrophoresis on a 1.5% agarose gel.
Restriction analysis of polymorphisms
Following the identification of the )24C fi T polymorphism in exon 1 by sequence analysis, restriction analysis with BbsI (New England Biolabs, Beverly, Mass.) was performed to detect this polymorphism according to the method of Mor-Cohen et al. (2001) . Exon 1 was amplified by using a reported primer set (Toh et al. 1999) ; the product was digested by 10 U BbsI for 12 h at 37°C and separated on a 1.5% agarose gel.
Results
Mutational analysis of the MRP2 mRNA from three DJS patients revealed two types of deletion mutation, c.2272del168 and c.1901del67, which were previously known as shown in Table 1 .
In the study of DJ1, the homozygous mutation c.2272del168, which causes skipping of exon 18, was detected by PCR of the MRP2 cDNA by using primer set G (forward: 5'-ggagatttggctgagattggagaga-3', reverse: 5'-cttcagatgcctgccattggaccta-3') designed by Wada et al. (1998) , and which covers c.2245-2608, and by direct sequencing of the PCR product (data not shown). The two daughters (DJ1/C1 and DJ1/C2) of DJ1 were heterozygous for this mutation (Table 2 ).
In the case of DJ2, a homozygous mutation of c.1901del67, which causes skipping of exon 15, was revealed by PCR amplification by using primer set E (forward: 5'-accttcattcagagaccaag-3', reverse: 5'-ggctgatatcaaggaggatt-3') as shown in Fig. 1A . One daughter and one of two siblings of DJ2 were heterozygous for this mutation (Table 2 ).
In the case of DJ3, as shown in Fig. 1A , the patient was heterozygous for c.1901del67; this result was supported by sequence analysis of exon 15 with the flanking intronic region, which revealed the 1967+2T fi C mutation of the splicing site (Fig. 1B) . In addition, sequencing analysis of exons 16 and 1 detected a novel missense mutation of 2026G fi C (G676R) in the first Walker A motif (Fig. 2) and a single nucleotide polymorphism (SNP) of )24C fi T in the non-coding region of exon 1 (Fig. 3) . The c.1901del67 mutation was detected in two other siblings and two daughters of DJ3. Mismatch PCR revealed that the 2026G fi C mutation was not distributed in the six siblings and two children (Table 2, Fig. 4) . With respect to the polymorphism )24C fi T, we also employed a restriction enzyme assay with BbsI; the results showed that his spouse and one daughter were heterozygous for this SNP, but other family members did not possess it (Fig. 4 ). There were no data for the parents and one sibling who were deceased. The new 2026G fi C mutation was not found in 50 healthy individuals (100 alleles). These results indicated that the mutations c.1901del67 and 2026G fi C were located on different alleles, and that 2026G fi C was a disease-associated mutation. DJ3 was a compound heterozygote for these mutations.
Discussion
In the present study, we have found a novel missense mutation that is predicted to affect the substitution of glycine 676 with arginine 676 (G676R), together with two known deletion mutations. Glycine 676 is one of the conserved amino acids (underlined) in the Walker A motif ( 671 GPVGSGKS 678 ) in the ABC of MRP2 protein (Taniguchi et al. 1996) .
Two mutations within the two ABCs in the MRP2 protein have been described previously in DJS patients in Japan as shown in Table 1 . One of these mutations (R768 W) is located within the first Walker C motif, and the other (Q1382R) lies within the second ABC (Toh . 1999) . The G676R conversion is the first reported mutation of the Walker A motif in MRP2 protein.
The Walker A motif consists of a sequence of eight amino acids (GPVGSGKS), and those underlined are consensus amino acids as described above. The G676R mutation is located at the 5'-flanking end of lysine, an amino acid shown to bind the c-phosphate of ATP (Konig et al. 2003) in NBD1. In the MRP1 protein, which is a member of the same family as MRP2, the substitution of lysine with methionine in NBD1 decreases ATP-binding to NBD2 and diminishes the transport activity of the protein (Gao et al. 2000; Hou et al. 2002) . In the transporters associated with antigen processing (TAP1 and TAP2), the conversion of lysine to methionine in the Walker A motif has been shown to cause a loss of transport activity (Lapinski et al. 2001) . Hashimoto et al. (2002) have reported that the artificial mutation K677R of the MRP2 gene and the missense mutation R768 W cause deficient maturation and impaired sorting.
The G676R mutation is associated with a change of hydrophobicity and electronic charge. It has been speculated that G676R causes two basic amino acids, arginine and lysine, to interact and/or a change in the conformation of NBD1. The local changes in NBD1 attributable to this mutation may cause impaired expression of the MRP2 variant or may decrease the function of the two ABCs and the transport activity of the protein. From the segregation analysis of the two mutations and the )24C fi T polymorphism shown in Fig. 4 , the segregation of c.1901del67 and )24C fi T in DJS3 and his family members demonstrates that these two variations were transferred independently. Thus, these two variants were on different alleles in DJS3, and )24C fi T was on the 2026G fi C variant allele. This was supported by the absence of )24C fi T in siblings without the 2026G fi C mutation.
Because the parents and one sibling were deceased, the genetic route and correct segregation of the G676R mutation remain unclear. Further investigation of the siblings of the parents and their family members may indicate whether this mutation is genetically transferred.
In conclusion, a novel disease-associated mutation, 2026G fi C, which is predicted to cause a G676R conversion in the MRP2 protein, has been detected in a DJS patient. This mutation is located within the first Walker A motif in the MRP2 protein. 3, 4) 
